Across TCGA pan-cancer cohorts, FKBPL Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FKBPL data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FKBPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FKBPL expression acts as an unfavorable survival marker.
HNSC and GBM are the cancer types where FKBPL Mutation most reproducibly stratifies survival.